Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$25.50 +2.2%	$21.92	$14.40 ▼ $47.00	$1.66B	1.22	1.04 million shs	1.40 million shs
INVA Innoviva	$20.92 +0.2%	$19.82	$16.67 ▼ $22.00	$1.31B	0.38	827,388 shs	895,595 shs
NVAX Novavax	$9.58 +1.6%	$7.15	$5.01 ▼ $15.22	$1.53B	2.5	7.77 million shs	7.19 million shs
PGNX Progenics Pharmaceuticals	$4.10	$4.10	$1.89 ▼ $6.37	$355.05M	1.89	1.16 million shs	34.93 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	+2.25%	+23.43%	+10.97%	+24.69%	-21.13%
INVA Innoviva	+0.19%	+14.07%	+3.31%	+12.59%	+13.94%
NVAX Novavax	+1.59%	+14.46%	+37.64%	+42.35%	-21.41%
PGNX Progenics Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.6088 of 5 stars	3.4	3.0	0.0	0.0	1.5	0.0	0.0
INVA Innoviva	4.3854 of 5 stars	3.5	1.0	0.0	4.2	3.2	1.7	1.9
NVAX Novavax	4.6368 of 5 stars	3.1	2.0	0.0	4.7	3.3	0.8	3.1
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.89	Moderate Buy	$51.75	102.94% Upside
INVA Innoviva	3.00	Buy	$42.75	104.35% Upside
NVAX Novavax	2.25	Hold	$15.86	65.52% Upside
PGNX Progenics Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PGNX, CLDX, NVAX, and INVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
8/11/2025	INVA Innoviva	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/13/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.02M	241.23	N/A	N/A	$9.87 per share	2.58
INVA Innoviva	$358.71M	3.66	$3.43 per share	6.10	$11.39 per share	1.84
NVAX Novavax	$682.16M	2.28	N/A	N/A	$0.23 per share	41.65
PGNX Progenics Pharmaceuticals	$34.99M	10.15	N/A	N/A	$0.54 per share	7.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	N/A
INVA Innoviva	$23.39M	$0.31	67.49	13.50	N/A	10.44%	18.67%	9.92%	N/A
NVAX Novavax	-$187.50M	$2.28	4.20	119.75	0.11	39.20%	-142.33%	28.65%	N/A
PGNX Progenics Pharmaceuticals	-$68.55M	-$0.80	N/A	N/A	N/A	-180.28%	-129.46%	-53.23%	N/A

Latest PGNX, CLDX, NVAX, and INVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/6/2025	Q2 2025	INVA Innoviva	$0.57	$0.77	+$0.20	$0.77	$87.10 million	$100.28 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PGNX Progenics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	19.67	19.67
INVA Innoviva	0.36	2.64	2.44
NVAX Novavax	5.93	2.36	2.34
PGNX Progenics Pharmaceuticals	0.99	2.12	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
INVA Innoviva	99.12%
NVAX Novavax	53.04%
PGNX Progenics Pharmaceuticals	70.96%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	4.40%
INVA Innoviva	2.25%
NVAX Novavax	1.00%
PGNX Progenics Pharmaceuticals	4.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
INVA Innoviva	100	62.78 million	61.36 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable
PGNX Progenics Pharmaceuticals	79	86.60 million	N/A	Optionable

PGNX, CLDX, NVAX, and INVA Headlines

Recent News About These Companies

Antibody–drug conjugates for cancer: poised to deliver?

October 28, 2024 | nature.comN

BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals

August 19, 2024 | br.advfn.com

PGNX_old Historical Data

October 28, 2023 | investing.com

Investing in Pharmaceutical Stocks

March 3, 2023 | fool.com

Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Quotes and News Summary

February 24, 2023 | benzinga.com

Opioid Induced Constipation (OIC) Drug Market Size in 2023 | NEWEST REPORT | Touch New Level in Forthcoming year till 2028

February 13, 2023 | marketwatch.com

Insights on the Flexible Manufacturing Systems for Pharmaceutical Industry Global Market to 2031 - by Product Type, Technology, End-user and Region

February 11, 2023 | finance.yahoo.com

I've Got an Options Bandage for a Sick Economy

June 19, 2022 | realmoney.thestreet.com

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

January 21, 2022 | thestreet.com

What Falling Estimates & Price Mean for Progenics (PGNX)

October 26, 2021 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNX, CLDX, NVAX, and INVA Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$25.50 +0.56 (+2.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$25.19 -0.31 (-1.21%)

As of 08/15/2025 05:44 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Innoviva NASDAQ:INVA

$20.92 +0.04 (+0.19%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$20.92 0.00 (0.00%)

As of 08/15/2025 05:53 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Novavax NASDAQ:NVAX

$9.58 +0.15 (+1.59%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$9.64 +0.05 (+0.57%)

As of 08/15/2025 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time